Beranda › Kanker Paru › Distrik Columbia
Uji klinis Kanker Paru di Distrik Columbia
27 studi untuk Kanker Paru mencari peserta di lokasi di Distrik Columbia.
Kota di Distrik Columbia
Teks studi resmi (Bahasa Inggris)
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- George Washington University Medical Center, Washington D.C.
Menerima pesertaFase 3
Usia 70 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06096844Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04267848Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- George Washington University Medical Center, Washington D.C.
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04181060Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Washington D.C.
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07127874A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Georgetown University, Washington D.C.
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07154290This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Washington DC Veterans Affairs Medical Center, Washington D.C.
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06758401Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- MedStar Georgetown University Hospital, Washington D.C.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06287775Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05786924A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Sibley Memorial Hospital, Washington D.C.
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Washington D.C.
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07038343Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Sibley Memorial Hospital, Washington D.C.
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06500481Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Georgetown University Medical Center, Washington D.C.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06162221Gilteritinib for the Treatment of ALK NSCLC
- Georgetown University, Washington D.C.
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT06225427Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Georgetown University Medical Center, Washington D.C.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT06922591Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
Menerima pesertaFase 2
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Cancer Support Community Research & Training Institute, Washington D.C.
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT02333604Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Sibley Memorial Hospital, Washington D.C.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06810544Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
- The George Washington University Hospital, Washington D.C.
Menerima pesertaFase 3
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06810375Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
- Medstar Washington Hospital Center, Washington D.C.
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Mar 2026 · NCT04499053Erector Spinae Block for Thoracic Surgery
- The George Washington University, Washington D.C.
Menerima pesertaFase 4
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 25 Feb 2026 · NCT05521789LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- MedStar Georgetown University Hospital, Washington D.C.
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jan 2026 · NCT06073431VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- The George Washington University Cancer Center (site 212), Washington D.C.
Menerima pesertaFase 1/2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT03556228A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- MedStar Health, Washington D.C.
Menerima pesertaSukarelawan sehat diterima
Usia 50 hingga 80 · Semua jenis kelamin · Diperbarui 27 Des 2024 · NCT04675476Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.